An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

J. Davies, A. Ingham*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume487
Issue number1-2
Early online date30 Mar 2015
DOIs
Publication statusPublished - 20 Jun 2015

Fingerprint

Cholecalciferol
Anticoagulants
Rodentia
Rodenticides
Genetic Selection
European Union
Dimethyl Sulfoxide
Ethanol
Skin
Mortality
Population
In Vitro Techniques

Bibliographical note

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).

Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.

Keywords

  • BPR
  • cholecalciferol
  • efficacy
  • regulation No. 528/2012
  • transdermal
  • rodenticide

Cite this

@article{762aa09aa8d54dacb522a5ae9aa87192,
title = "An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management",
abstract = "The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15{\%} (v/v) PEG 200 and 20{\%} (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100{\%} mortality in a rat population in 64.4 h (±22 h).",
keywords = "BPR, cholecalciferol, efficacy, regulation No. 528/2012, transdermal, rodenticide",
author = "J. Davies and A. Ingham",
note = "Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.",
year = "2015",
month = "6",
day = "20",
doi = "10.1016/j.ijpharm.2015.03.055",
language = "English",
volume = "487",
pages = "101--109",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management. / Davies, J.; Ingham, A.

In: International Journal of Pharmaceutics, Vol. 487, No. 1-2, 20.06.2015, p. 101-109.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An in-vitro-in-vivo model for the transdermal delivery of cholecalciferol for the purposes of rodent management

AU - Davies, J.

AU - Ingham, A.

N1 - Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). Funding: European Union’s Seventh Framework Programme managed by REA Research Executive Agency http://ec.europa.eu/rea (FP7/2007-2013) under grant Project Reference 286852.

PY - 2015/6/20

Y1 - 2015/6/20

N2 - The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

AB - The natural selection of anticoagulant resistant rats has resulted in a need for an alternative to anticoagulant rodenticides which differs in both active ingredient and in the method of dosing. Cholecalciferol toxicity to rodents using the dermal route is demonstrated using a variety of penetration enhancing formulations in two in-vitro models and finally in-vivo. A 1 ml dose of 50/50 (v/v) DMSO/ethanol containing 15% (v/v) PEG 200 and 20% (w/v) cholecalciferol was judged as 'sufficiently effective' in line with the European Union's Biocidal Products Regulation (No. 528/2012) during in-vivo studies. This dose was found to cause 100% mortality in a rat population in 64.4 h (±22 h).

KW - BPR

KW - cholecalciferol

KW - efficacy

KW - regulation No. 528/2012

KW - transdermal

KW - rodenticide

UR - http://www.scopus.com/inward/record.url?scp=84927718041&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2015.03.055

DO - 10.1016/j.ijpharm.2015.03.055

M3 - Article

AN - SCOPUS:84927718041

VL - 487

SP - 101

EP - 109

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -